Literature DB >> 23477830

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Rizwan Haq1, Jonathan Shoag, Pedro Andreu-Perez, Satoru Yokoyama, Hannah Edelman, Glenn C Rowe, Dennie T Frederick, Aeron D Hurley, Abhinav Nellore, Andrew L Kung, Jennifer A Wargo, Jun S Song, David E Fisher, Zolt Arany, Hans R Widlund.   

Abstract

Activating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1α. We further show that a target of BRAF, the melanocyte lineage factor MITF, directly regulates the expression of PGC1α. Melanomas with activation of the BRAF/MAPK pathway have suppressed levels of MITF and PGC1α and decreased oxidative metabolism. Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23477830      PMCID: PMC3635826          DOI: 10.1016/j.ccr.2013.02.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  77 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer.

Authors:  Geoffrey D Girnun
Journal:  Semin Cell Dev Biol       Date:  2012-01-21       Impact factor: 7.727

Review 3.  Metabolic control through the PGC-1 family of transcription coactivators.

Authors:  Jiandie Lin; Christoph Handschin; Bruce M Spiegelman
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

4.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

5.  Use of Dinitrophenol in Nutritional Disorders : A Critical Survey of Clinical Results.

Authors:  M L Tainter; W C Cutting; A B Stockton
Journal:  Am J Public Health Nations Health       Date:  1934-10

6.  Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction.

Authors:  M Colombi; K D Molle; D Benjamin; K Rattenbacher-Kiser; C Schaefer; C Betz; A Thiemeyer; U Regenass; M N Hall; C Moroni
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

7.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

8.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

9.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

10.  Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Authors:  R E Board; G Ellison; M C M Orr; K R Kemsley; G McWalter; L Y Blockley; S P Dearden; C Morris; M Ranson; M V Cantarini; C Dive; A Hughes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more
  360 in total

Review 1.  Mitochondrial dynamics as regulators of cancer biology.

Authors:  Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

2.  Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2high Breast Cancer.

Authors:  Katerina Rohlenova; Karishma Sachaphibulkij; Jan Stursa; Ayenachew Bezawork-Geleta; Jan Blecha; Berwini Endaya; Lukas Werner; Jiri Cerny; Renata Zobalova; Jacob Goodwin; Tomas Spacek; Elham Alizadeh Pesdar; Bing Yan; Maria Nga Nguyen; Magdalena Vondrusova; Margaryta Sobol; Petr Jezek; Pavel Hozak; Jaroslav Truksa; Jakub Rohlena; Lan-Feng Dong; Jiri Neuzil
Journal:  Antioxid Redox Signal       Date:  2016-08-22       Impact factor: 8.401

Review 3.  Potential applications for biguanides in oncology.

Authors:  Michael Pollak
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.

Authors:  Robert A Mook; Jiangbo Wang; Xiu-Rong Ren; Minyong Chen; Ivan Spasojevic; Larry S Barak; H Kim Lyerly; Wei Chen
Journal:  Bioorg Med Chem       Date:  2015-08-10       Impact factor: 3.641

5.  Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma.

Authors:  David B Lombard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Discov       Date:  2019-04       Impact factor: 39.397

6.  Increasing the level of peroxisome proliferator-activated receptor γ coactivator-1α in podocytes results in collapsing glomerulopathy.

Authors:  Szu-Yuan Li; Jihwan Park; Chengxiang Qiu; Seung Hyeok Han; Matthew B Palmer; Zoltan Arany; Katalin Susztak
Journal:  JCI Insight       Date:  2017-07-20

7.  Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer?

Authors:  Dieter A Wolf
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

8.  MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma.

Authors:  Anupama Sahoo; Sanjaya K Sahoo; Piyush Joshi; Bongyong Lee; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2018-08-01       Impact factor: 8.551

9.  A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors.

Authors:  Mitchell P Levesque; Werner J Kovacs; Andrea Aloia; Daniela Müllhaupt; Christophe D Chabbert; Tanja Eberhart; Stefanie Flückiger-Mangual; Ana Vukolic; Ossia Eichhoff; Anja Irmisch; Leila T Alexander; Ernesto Scibona; Dennie T Frederick; Benchun Miao; Tian Tian; Chaoran Cheng; Lawrence N Kwong; Zhi Wei; Ryan J Sullivan; Genevieve M Boland; Meenhard Herlyn; Keith T Flaherty; Nicola Zamboni; Reinhard Dummer; Gao Zhang; Wilhelm Krek
Journal:  Clin Cancer Res       Date:  2019-08-02       Impact factor: 12.531

10.  Geroncogenesis: metabolic changes during aging as a driver of tumorigenesis.

Authors:  Lindsay E Wu; Ana P Gomes; David A Sinclair
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.